The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study Jerry Bagel, MD, Kristina Callis Duffin, MD, MS, Angela Moore, MD, Laura K. Ferris, MD, PhD, Kimberly Siu, MD, MPH, Jennifer Steadman, MSW, Farid Kianifard, PhD, Judit Nyirady, MD, MBA, Mark Lebwohl, MD Journal of the American Academy of Dermatology Volume 77, Issue 4, Pages 667-674 (October 2017) DOI: 10.1016/j.jaad.2017.05.033 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 1 Study design. Journal of the American Academy of Dermatology 2017 77, 667-674DOI: (10.1016/j.jaad.2017.05.033) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 2 Patient disposition. Journal of the American Academy of Dermatology 2017 77, 667-674DOI: (10.1016/j.jaad.2017.05.033) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 3 Efficacy over time. The secukinumab 300 mg and placebo cohorts were compared by different scoring systems from baseline to week 24. A, PSSI 90 response. B, IGA mod 2011 0/1 response (scalp only). C, PSSI 100 response. IGA mod 2011, Investigator's Global Assessment modified 2011; PSSI, Psoriasis Scalp Severity Index. *P < .05; †P ≤ .001; ‡P < .01; §At week 12, all patients but 1 switched to secukinumab 300 mg. Journal of the American Academy of Dermatology 2017 77, 667-674DOI: (10.1016/j.jaad.2017.05.033) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions
Fig 4 Speed of response. The percent change in PSSI score in the secukinumab 300 mg and placebo cohorts from baseline to week 12 are indicated. PSSI, Psoriasis Scalp Severity Index. Journal of the American Academy of Dermatology 2017 77, 667-674DOI: (10.1016/j.jaad.2017.05.033) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions